Tenax Therapeutics (TENX) Net Income towards Common Stockholders (2016)
Historic Net Income towards Common Stockholders for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to $33.9 million.
- Tenax Therapeutics' Net Income towards Common Stockholders rose 37972.22% to $33.9 million in Q4 2016 from the same period last year, while for Sep 2017 it was $33.9 million, marking a year-over-year increase of 25913.32%. This contributed to the annual value of -$17.6 million for FY2024, which is 12643.43% down from last year.
- As of Q4 2016, Tenax Therapeutics' Net Income towards Common Stockholders stood at $33.9 million, which was up 37972.22% from -$4.5 million recorded in Q3 2016.
- In the past 5 years, Tenax Therapeutics' Net Income towards Common Stockholders registered a high of $118.0 million during Q2 2013, and its lowest value of -$12.1 million during Q4 2015.
- Moreover, its 4-year median value for Net Income towards Common Stockholders was -$3.0 million (2012), whereas its average is $22.4 million.
- The largest annual percentage gain for Tenax Therapeutics' Net Income towards Common Stockholders in the last 5 years was 371057.81% (2012), contrasted with its biggest fall of 35790.41% (2012).
- Tenax Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$1.6 million in 2012, then soared by 7711.24% to $118.0 million in 2013, then plummeted by 110.26% to -$12.1 million in 2015, then skyrocketed by 379.72% to $33.9 million in 2016.
- Its last three reported values are $33.9 million in Q4 2016, -$4.5 million for Q3 2016, and -$4.7 million during Q2 2016.